title: Pirfenidone.
abstract: Pirfenidone, an antifibrotic tissue growth antagonist, is in development for the potential treatment of fibrotic diseases including renal, liver and pulmonary fibrosis and for multiple sclerosis.
authors.affiliation: Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-9, New Orleans, LA 70112, USA. jlasky@tulane.edu
authors.forename: Joseph
authors.initials: J
authors.lastname: Lasky
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005355:Fibrosis / Q000188:drug therapy*; D006801:Humans; D011728:Pyridones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
chemical_list: D011728:Pyridones; C093844:pirfenidone